Robert C. Smallridge, M.D.

Closed for Enrollment

• A Phase IIA, Open-Label Study to Assess the Safety and Efficacy of a Single or Multiple Intravenous (IV) Dose of VB-111 in Subjects with Advanced Differentiated Thyroid Cancer (DTC) Rochester, Minn., Jacksonville, Fla.

  The purpose of this study is to examine the safety and evaluate the response of VB-111 on DTC.

• Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy Jacksonville, Fla., Rochester, Minn.

  This phase II trial studies how well cabozantinib-s-malate works in treating patients with thyroid cancer that does not respond to treatment. Cabozantinib-s-malate may stop the growth of thyroid cancer by blocking some of the enzymes needed for cell growth. Cabozantinib-s-malate may also stop the growth of thyroid cancer by blocking blood flow to the tumor.